IN2014DN09618A - - Google Patents

Info

Publication number
IN2014DN09618A
IN2014DN09618A IN9618DEN2014A IN2014DN09618A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A IN 9618DEN2014 A IN9618DEN2014 A IN 9618DEN2014A IN 2014DN09618 A IN2014DN09618 A IN 2014DN09618A
Authority
IN
India
Prior art keywords
fusion protein
plasmid
expression
fused
generation
Prior art date
Application number
Other languages
English (en)
Inventor
Dennis J Kopecko
Manuel Osorio
Monica R Foote
Original Assignee
Us Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Sec Dep Of Health And Human Services filed Critical Us Sec Dep Of Health And Human Services
Publication of IN2014DN09618A publication Critical patent/IN2014DN09618A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN9618DEN2014 2012-05-23 2013-05-22 IN2014DN09618A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650676P 2012-05-23 2012-05-23
PCT/US2013/042240 WO2013177291A1 (fr) 2012-05-23 2013-05-22 Salmonella typhi ty21a exprimant la protéine de fusion f1-v et ses utilisations

Publications (1)

Publication Number Publication Date
IN2014DN09618A true IN2014DN09618A (fr) 2015-07-31

Family

ID=48539444

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9618DEN2014 IN2014DN09618A (fr) 2012-05-23 2013-05-22

Country Status (7)

Country Link
US (1) US9409956B2 (fr)
EP (1) EP2852405B1 (fr)
JP (1) JP6216371B2 (fr)
CN (1) CN104470537B (fr)
IL (1) IL235615A0 (fr)
IN (1) IN2014DN09618A (fr)
WO (1) WO2013177291A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
GB9326425D0 (en) 1993-12-24 1994-02-23 Secr Defence Vaccine compositions
EP0772619B2 (fr) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Oligonucleotides immunomodulateurs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU710181B2 (en) * 1995-03-13 1999-09-16 Secretary Of State For Defence, The Vaccines for plague
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
WO2000014240A2 (fr) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Mutants attenues de spi2 de salmonelles utilises comme porteurs d'antigenes
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
WO2005026203A2 (fr) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Promoteurs d'adn et vaccins contre l'anthrax
AU2004296394A1 (en) * 2003-12-09 2005-06-23 Avant Immunotherapeutics, Inc. Orally-administered live bacterial vaccines for plague
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP1921149A1 (fr) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganimses portant des séquences nucléotidiques codant pour des antigènes et des toxines, procédé de fabrication, et leurs utilisations

Also Published As

Publication number Publication date
JP2015519061A (ja) 2015-07-09
EP2852405B1 (fr) 2019-03-13
EP2852405A1 (fr) 2015-04-01
IL235615A0 (en) 2015-01-29
US20150152144A1 (en) 2015-06-04
WO2013177291A1 (fr) 2013-11-28
US9409956B2 (en) 2016-08-09
CN104470537A (zh) 2015-03-25
CN104470537B (zh) 2017-04-26
JP6216371B2 (ja) 2017-10-18
WO2013177291A8 (fr) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2014008441A (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
MY186535A (en) Novel european prrsv strain
MX2015005797A (es) Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica.
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
HK1142809A1 (en) Multimeric multiepitope influenza vaccines
NZ703701A (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
IN2015DN02771A (fr)
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
IN2014DN07956A (fr)
MX358201B (es) Vacuna novedosa shigella atenuada viva.
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
DK201370530A (en) Salmonid alphavirus vaccine
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
IN2014DN09618A (fr)
MX350460B (es) Enjuagues bucales y composiciones de tratamiento de la sensibilidad dental.
MX367780B (es) Complejo inmunogénico para vacunación y método de obtención.
WO2014144153A3 (fr) Immunogènes de métapneumovirus et matériels et méthodes associés
WO2012178078A3 (fr) Utilisation d'une yscf, d'une yscf tronquée et d'homologues de l'yscf comme adjuvants